2L
LFCR icon

22NW LP’s Lifecore Biomedical LFCR Stock Holding History

22NW LP’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.22K Hold
1,254
– – 0.01% 14
2026
Q1 		$18.9M Hold
1,254
– – 12.93% 3
2025
Q4 		$23M Hold
1,254
– – 9.69% 3
2025
Q3 		$20.1M Sell
1,254
-262,926
-100% -$1.99M 9.49% 3
2025
Q2 		$22.6M Sell
264,180
-1,490,981
-85% -$10.1M 14.25% 2
2025
Q1 		$29.8M Hold
1,755,161
– – 20% 1
2024
Q4 		$31.1M Hold
1,755,161
– – 19.65% 2
2024
Q3 		$23.7M Hold
1,755,161
– – 19.83% 2
2024
Q2 		$24M Hold
1,755,161
– – 20.48% 2
2024
Q1 		$9.32M Hold
1,755,161
– – 8.03% 4
2023
Q4 		$10.9M Hold
1,755,161
– – 7.08% 5
2023
Q3 		$13.3M Hold
1,755,161
– – 9.44% 5
2023
Q2 		$17M Hold
1,755,161
– – 10.6% 4
2023
Q1 		$6.63M Hold
1,755,161
– – 4.08% 10
2022
Q4 		$11.4M Hold
1,755,161
– – 6.14% 7
2022
Q3 		$15.6M Buy
1,755,161
+412,945
+31% +$4.2M 8.82% 3
2022
Q2 		$13.4M Buy
1,342,216
+118,306
+10% +$1.17M 7.1% 5
2022
Q1 		$14.2M Buy
1,223,910
+735
+0.1% +$8.19K 5.15% 8
2021
Q4 		$13.6M Buy
1,223,175
+369,874
+43% +$3.59M 4.2% 10
2021
Q3 		$7.87M Buy
853,301
+303,042
+55% +$3.3M 2.34% 16
2021
Q2 		$6.19M Buy
+550,259
New +$6.34M 1.66% 24

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

22NW LP's LFCR Position: Q2 2026 in Review

22NW LP held its Lifecore Biomedical (LFCR) position steady in Q2 2026 at 1,254 shares worth $6.22K. The position accounts for 0.01% of the portfolio, ranked #14.

22NW LP first reported a position in LFCR in Q2 2021 and has held it in 21 quarters since. The position peaked at $31.1M in Q4 2024. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • 22NW LP held 1,254 shares of Lifecore Biomedical worth $6.22K as of Q2 2026.
  • 22NW LP left its Lifecore Biomedical share count unchanged in Q2 2026.
  • Lifecore Biomedical made up 0.01% of 22NW LP's portfolio in Q2 2026, its #14 holding.
  • 22NW LP first reported a position in Lifecore Biomedical in Q2 2021 and has held it in 21 quarters since.
  • 22NW LP's Lifecore Biomedical position peaked at $31.1M in Q4 2024.
  • 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on 22NW LP's 13F filing for Q2 2026, filed 14 Aug 2026.